

- Complicated skin and soft tissue infections (cSSTIs) are associated with significant morbidity and mortality, require resource intensive treatment and can complicate clinically significant medical conditions.
- *Meticillin-Resistant Staphylococcus aureus* (MRSA) is recognized as the greatest antibiotic resistance concern in the management of cSSTIs.
- A previously published economic model was adapted for the Greek hospital setting, to identify healthcare resource use and MRSA-cSSTI total inpatient costs, along with costs associated with different antibiotics.
- The total annual inpatient cost for MRSA-cSSTIs in Greece was estimated at €29,196,218. At the baseline case scenario, linezolid was associated with the lowest total management costs for a “typical” MRSA - cSSTI patient.
- Development of hospital strategies to facilitate early discharge of patients such as the introduction of clinical criteria and guidelines for the switch to oral MRSA-cSSTI treatments, could result in substantial savings for the Greek hospital budget.

This summary slide represents the opinions of the authors. Sponsorship for this study was funded by Pfizer Hellas, Athens, Greece. For a full list of acknowledgments and conflicts of interest for all authors of this article, please see the full text online. Copyright © The Authors 2014. Creative Commons Attribution Noncommercial License (CC BY-NC).